Combined Metabolic Activator Supplementation in Subjects Diagnosed With Gout
A Phase 3, Randomised, Double-Blind, Placebo-Controlled, Multi-centre Study to Evaluate the Efficacy, Safety, and Tolerability of Combined Metabolic Activator (CMA2) Supplementation in Individuals With Hyperuricemia Associated With Gout
This will be a randomised, double-blind, placebo-controlled, multi-centre study with the aim to establish metabolic improvements in individuals diagnosed with hyperuricemia associated with gout by treatment with CMA2 including N-acetyl-L-cysteine (NAC), L-carnitine-L-tartrate (LCAT), nicotinamide (niacinamide), and L-serine for 4 weeks.
Studienübersicht
Status
Status
Bedingungen
Bedingungen
Intervention / Behandlung
Intervention / Behandlung
Detaillierte Beschreibung
Consenting participants will be screened for eligibility (Visit 1; screening) according to study-specific eligibility criteria within 7 days prior to randomisation and start of investigational medicinal product (IMP) administration.
Eligible participants will be randomised on Day 1 (Visit 2) to 4 weeks of twice daily (b.i.d.) oral treatment of either CMA2 or placebo (1:1). The first dose will be administered at the study clinic. The participants will be observed for 2 hours post dose for the development of any allergic reactions or intolerance after taking the first dose.
Visits at the study site will be performed at Day 1 (Visit 2), Day 14 (Visit 4) and Day 28 (Visit 6; end of in study treatment). There will be telephone follow up visits at Day 7 (Visit 3) and Day 21(Visit 5) checking safety, concomitant medications and IMP compliance. A final follow-up visit for safety assessments will be conducted in a subgroup of patients 14 days after the end of treatment (Day 42; Visit 7) during an IMP-free follow-up period to assess safety and concomitant medications.
The following clinical scales will be used to evaluate the effect of CMA2 on uric acid decline, hsCRP and daily life activity: Serum Uric Acid Levels, hsCRP, number of flares according to the GAFFO criteria, HAQ-DI, SF-36, PGA (100 mm).
Plasma samples will be collected for advanced metabolomics, proteomics, and lipidomics analysis.
Optionally, synovial samples will be collected for advanced metabolomics, proteomics, and lipidomics analysis. Optionally, gut and saliva samples will be collected for metagenomics analysis of gut and oral microbiome.
Laboratory and clinical safety parameters will be monitored at pre-specified time-points.
Studientyp
Studientyp
Einschreibung (Geschätzt)
Einschreibung
Phase
Phase
- Phase 3
Kontakte und Standorte
Studienkontakt
Studienkontakt
- Name: Gökhan Gönenli, Uzm. Dr. M.
- Telefonnummer: + 90 532 405 76 82
- E-Mail: mgonenli@ku.edu.tr
Studieren Sie die Kontaktsicherung
- Name: Müjdat Zeybel, Prof. Dr.
- Telefonnummer: + 90 532 604 83 81
- E-Mail: mzeybel@ku.edu.tr
Studienorte
-
-
-
Ankara, Türkei (türkiye)
- Noch keine Rekrutierung
- Ankara Bilkent City Hospital
-
Kontakt:
- Hakan Babaoğlu
-
Hauptermittler:
- Hakan Babaoğlu, Assoc. Prof. Dr.
-
Antalya, Türkei (türkiye)
- Noch keine Rekrutierung
- Alanya Training and Research Hospital
-
Kontakt:
- Şakir Özgür Keskek
-
Hauptermittler:
- Şakir Özgür Keskek, Prof. Dr.
-
Erzurum, Türkei (türkiye)
- Noch keine Rekrutierung
- Atatürk University Research Hospital
-
Kontakt:
- Bülent Albayrak
-
Hauptermittler:
- Bülent Albayrak, Assoc. Prof. Dr.
-
Erzurum, Türkei (türkiye)
- Noch keine Rekrutierung
- Erzurum City Hospital
-
Kontakt:
- Kenan Çadırcı
-
Hauptermittler:
- Kenan Çadırcı, Prof. Dr.
-
Eskişehir, Türkei (türkiye)
- Rekrutierung
- Eskişehir Osmangazi University Faculty of Medicine Hospital
-
Kontakt:
- Nazife Şule Bige Yaşar
-
Hauptermittler:
- Nazife Şule Bige Yaşar, Prof. Dr.
-
Istanbul, Türkei (türkiye)
- Noch keine Rekrutierung
- Göztepe Prof. Dr. Süleyman Yalçın City Hospital
-
Kontakt:
- Esen Kasapoğlu
-
Hauptermittler:
- Esen Kasapoğlu, Prof. Dr.
-
Istanbul, Türkei (türkiye)
- Noch keine Rekrutierung
- Istanbul University-Cerrahpaşa Faculty of Medicine Hospital
-
Kontakt:
- Gülen Hatemi
-
Hauptermittler:
- Gülen Hatemi, Prof. Dr.
-
Istanbul, Türkei (türkiye)
- Noch keine Rekrutierung
- Kanuni Sultan Süleyman Training and Research Hospital
-
Kontakt:
- Ozan Cemal İçaçan
-
Hauptermittler:
- Ozan Cemal İçaçan, Specialist. Dr.
-
Istanbul, Türkei (türkiye)
- Noch keine Rekrutierung
- Kartal Dr. Lütfi Kırdar City Hospital
-
Kontakt:
- Mehmet Engin Tezcan
-
Hauptermittler:
- Mehmet Engin Tezcan, Specialist. Dr.
-
Istanbul, Türkei (türkiye)
- Rekrutierung
- Koç University Hospital
-
Kontakt:
- Gökhan Gönenli
- E-Mail: mgonenli@ku.edu.tr
-
Hauptermittler:
- Gökhan Gönenli, Specialist. Dr.
-
Istanbul, Türkei (türkiye)
- Noch keine Rekrutierung
- Sancaktepe Şehit Prof. Dr. İlhan Varank Training and Research Hospital
-
Kontakt:
- Kadem Arslan
-
Hauptermittler:
- Kadem Arslan, Assoc. Prof. Dr.
-
Istanbul, Türkei (türkiye)
- Noch keine Rekrutierung
- Sultan 2nd Abdülhamid Han Training and Research Hospital
-
Kontakt:
- Memnune Sena Ulu
-
Hauptermittler:
- Memnune Sena Ulu, Prof. Dr.
-
-
Teilnahmekriterien
Zulassungskriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Beschreibung
Inclusion Criteria:
- Men and women ≥ 18 years of age.
- Individuals with elevated uric acid blood levels (7 mg/dl) and at least one episode of gout during the last three years.
- Diagnosis of gout based on 2015 American College of Rheumatology-European Union League Against Rheumatism (ACR-EULAR) criteria.
- Able to give written informed consent for participation in the study by the patient and/or legal representatives.
Exclusion Criteria:
-
Patients who have received uric acid-lowering therapy with a change in dose within 1 month prior to inclusion.
-
Acute gout flare within 14 days prior to randomization (i.e., any gouty arthritis episode with pain or swelling that has not fully resolved ≤14 days before randomization). Definition of Resolved (for the eligibility assessment): absence of joint pain at rest and no visible swelling at the previously affected joint(s) for at least 48 hours, and no requirement for escalation of anti-inflammatory therapy within that period.
-
History of stroke.
-
History of brain trauma < 14 days.
-
Uncontrolled diagnosed depression.
-
Uncontrolled diabetes (HbA1c > 8.4%).
-
Severe swallowing problems.
-
PEG-feeding.
-
Chronic diarrhoea.
-
Chronic kidney disease with S-creatinine > 1.30 mg/dL.
-
Estimated glomerular filtration rate (eGFR) of <30 mL/min/1.73 m2 in the Screening Phase
-
Active bronchial asthma at the time of screening.
-
History of phenylketonuria
-
Known allergy for substances used in the study
-
Known allergy for strawberry
-
Known active malignancy
-
Known active psoriasis
-
Use of dietary supplements such as vitamins, omega-3 products, or plant stanol/sterol products later than one (1) week prior to inclusion.
-
Use of anti-microbial agents later than one (1) week prior to inclusion.
-
Drug and/or alcohol abuse.
-
Participants considered as inappropriate for this study for any reason (noncompliance etc.) per investigator assessment.
-
Administration of another new chemical entity (defined as a compound that has not been approved for marketing) or has participated in any other clinical study that included drug treatment with the last administration within 3 months prior to administration of IMP in this study.
-
Females who are breastfeeding or pregnant at screening (as documented by a positive beta human chorionic gonadotropin [β-hCG] test)
-
Females of childbearing potential who:
Within 28 days before study entry, did not use a highly effective method of contraception, which includes any of the following:
- total abstinence (if it is their preferred and usual lifestyle)
- an intrauterine device or intrauterine hormone-releasing system (IUS)
- a contraceptive implant
- an oral contraceptive (Subject must have been on a stable dose of the same oral contraceptive product for at least 28 days before dosing and must agree to stay on the same dose of the oral contraceptive throughout the study and for 28 days after study drug discontinuation.)
- have a vasectomized partner with confirmed azoospermia. Do not agree to use a highly effective method of contraception (as described above) throughout the entire study period and for 28 days after study drug discontinuation.
It is permissible that if a highly effective method of contraception is not appropriate or acceptable to the subject, then the subject must agree to use a medically acceptable method of contraception, ie, double-barrier methods of contraception such as latex or synthetic condom plus diaphragm or cervical/vault cap with spermicide.
NOTE: Females of childbearing potential must have documented tubal ligation or hysterectomy; or be post-menopausal (defined as 12 months of amenorrhea [in questionable cases a blood sample with simultaneous follicle stimulating hormone (FSH) 25-140 IE/L and estradiol <200 pmol/L is confirmatory]).
-
Male participants who:
- Plan to conceive a child or donate sperm during the study treatment period and for at least 90 days after the last dose of investigational product, or
- Are unwilling to use effective contraception during the study and for at least 90 days after the last dose of investigational product.
-
Currently has secondary hyperuricemia:
1) Lesch-Nyhan syndrome 2) Phosphoribosylpyrophosphate synthetase superactivity 3) Congenital myogenic hyperuricemia 4) Hematopoietic neoplasms (acute leukemia, lymphoma malignant, myeloproliferative disorder, myelodysplastic syndrome, etc) 5) Solid tumors (breast cancer, seminoma, sarcoma, Wilms tumor, small cell lung cancer, etc) 6) Non-neoplastic diseases (psoriasis vulgaris, secondary polycythemia, hemolytic anemia) 7) Rhabdomyolysis 8) Hypothyroidism 9) Polycystic kidney 10) Lead poisoning/lead nephropathy 11) Down's syndrome 12) Familial juvenile gouty nephropathy 13) Hyperlactacidemia 14) Glycogen storage disease type 1 27. Participants who are on the following treatment are required to be on a stable dose and same mode of administration for at least 14 days prior to screening and to keep the stable during the study. Participants are not permitted to initiate these drugs within 14 days prior to screening and during the study.
- Dietary and physical therapy for the underlying disease
- Drugs or containing compound preparations that potentially affect SUA level:
- Immunosuppressants (mizoribine, cyclosporin, tacrolimus hydrate)
- Antituberculous drugs (pyrazinamide, ethambutol hydrochloride)
- Hyperlipidemia drugs (fenofibrate, atorvastatin, rosuvastatin, pitavastatin)
- Antihypertensives (losartan potassium)
- Diuretics (thiazide diuretics, loop diuretics)
- Sodium-dependent glucose transporter (SGLT) 2 inhibitors
- Theophylline
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Unterstützende Pflege
- Zuteilung: Zufällig
- Interventionsmodell: Parallele Zuordnung
- Maskierung: Doppelt
Anzahl der Arme
Waffen und Interventionen
Teilnehmergruppe / ArmTeilnehmergruppe / Arm |
Intervention / BehandlungIntervention / Behandlung |
|---|---|
|
Experimental: Behandlungsarm
|
A total of 20g of CMA2 with strawberry aroma and colouring agent will be given. The IMP will be provided as a soluble powder packed as individual dosages in identical sachets. The powder should be dissolved in 200 ml preferably cold water before use. The powder can also be used on yoghurt or other food. The subjects will take two daily oral doses of the IMP, one dose just after breakfast and one dose just after dinner. Subjects who cannot tolerate (e.g., diarrhoea) taking full dose will be withdrawn from the study. |
|
Placebo-Komparator: Placebo-Arm
|
As placebo, a total of 20g of compound primarily containing collagen and maltodextrin will be administered. Placebo contains strawberry aroma flavouring and colouring agent. |
Was misst die Studie?
Primäre Ergebnismessungen
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
To evaluate the effect of 4-weeks administration of CMA2 treatment on serum uric acid levels in participants diagnosed with hyperuricemia associated with gout, as compared with placebo.
Zeitfenster: 4 weeks
|
Absolute change in serum uric acid levels from baseline to end-of-treatment (4 weeks). |
4 weeks
|
Sekundäre Ergebnismessungen
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
To evaluate the effect of 4 weeks of CMA2 treatment on patient global assessment (PGA, 100 mm) compared with placebo.
Zeitfenster: 4 weeks
|
Change in Patient Global Assessment (PGA, 100 mm) score from baseline to end-of-treatment. PGA is assessed using a visual analogue scale (VAS) ranging from 0 to 10 or 0 to 100, where higher scores indicate worse disease activity. |
4 weeks
|
|
To evaluate the effect of 4 weeks of CMA2 treatment on High Sensitivity C-reactive Protein (hsCRP) levels compared with placebo.
Zeitfenster: 4 weeks
|
Percentage change in High Sensitivity C-reactive Protein (hsCRP) levels from baseline to end-of-treatment. |
4 weeks
|
|
To evaluate the proportion of participants achieving serum uric acid levels < 6 mg/dL.
Zeitfenster: 4 weeks
|
Proportion of patients with a serum uric acid level <6 .0 mg/dL at end-of-treatment. |
4 weeks
|
|
To evaluate the effect of 2-weeks administration of CMA2 treatment on serum uric acid levels compared with placebo.
Zeitfenster: 2 weeks
|
Change in serum uric acid levels from baseline to 2-weeks. |
2 weeks
|
|
To evaluate patient adherence to the twice-daily treatment regimen.
Zeitfenster: 4 weeks
|
Percentage of expected twice-daily study drug doses successfully administered, as assessed by sachet counts. |
4 weeks
|
|
To evaluate the incidence of adverse events (AEs).
Zeitfenster: 6 weeks
|
The percentage of subjects experiencing at least one AE during the study period. |
6 weeks
|
|
To evaluate the severity of AEs.
Zeitfenster: 6 weeks
|
The incidence of AEs categorized by maximum severity grade. |
6 weeks
|
|
To evaluate the incidence of serious adverse events (SAEs).
Zeitfenster: 6 weeks
|
The percentage of subjects experiencing at least one SAE during the study period. |
6 weeks
|
Mitarbeiter und Ermittler
Sponsor
Sponsor
Ermittler
Ermittler
- Hauptermittler: Gökhan Gönenli, Uzm. Dr. M., Koc University Hospital
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn (Tatsächlich)
Studienbeginn
Primärer Abschluss (Geschätzt)
Primärer Abschluss
Studienabschluss (Geschätzt)
Studienabschluss
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Tatsächlich)
Zuerst gepostet
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes Update gepostet
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Schlüsselwörter
Zusätzliche relevante MeSH-Bedingungen
Andere Studien-ID-Nummern
Andere Studien-ID-Nummern
- SB-GOUT-001
Plan für individuelle Teilnehmerdaten (IPD)
Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?
Arzneimittel- und Geräteinformationen, Studienunterlagen
Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt
Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .